股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司*（「本公司」） *僅供識別 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02268 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.00005 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | 0.00005 | ...

Market Overview - The Hong Kong stock market showed a rebound in sentiment, with the Hang Seng Technology Index rising by 1.45% to above 5600 points, while the Hang Seng Index increased by 0.68% to 25935 points, and the National Enterprises Index rose by 0.86% to 9106 points [1][2]. Sector Performance - Large technology stocks collectively rose, with notable gains from Xiaomi (over 4%) and Meituan (over 2%). The pharmaceutical sector saw a surge in orders for flu medications, with some stocks in this category performing strongly [2][4]. - The semiconductor sector was active, with companies like Cambrian increasing chip production by three times, leading to a rise in semiconductor stocks [2][9]. - The biopharmaceutical sector experienced significant gains, with WuXi AppTec rising over 9% and other related stocks also showing strong performance due to increased demand for flu medications [6][8]. - The automotive, real estate, and pharmaceutical sectors showed positive movements, while the restaurant and gaming sectors faced declines [3][13][15]. Notable Stocks - Horizon Robotics saw a rise of over 6%, while Xiaomi and Trip.com also reported gains of over 4% and 3%, respectively [4][5]. - In the biopharmaceutical space, WuXi AppTec and other related stocks saw increases of over 8% [6]. - The robotics sector was strong, with companies like CloudMinds and others showing significant gains [7][8]. - The entertainment sector also saw some upward movement, with Lemon Films rising over 5% [11][12]. Capital Flows - Southbound funds recorded a net inflow of 1.48 billion HKD, indicating positive investor sentiment towards Hong Kong stocks [19]. Future Outlook - Analysts predict that the Hong Kong stock market may experience fluctuations in the coming months, with the Hang Seng Index expected to range between 23500 and 30500 points in 2026. Recommendations include buying on dips and focusing on sectors such as technology, high-end manufacturing, and renewable energy [21].

12月4日，香港恒生指数收涨0.68%，恒生科技指数涨1.45%。 | 代码 | 名称 | 现价 涨跌 | | 涨跌幅 | | --- | --- | --- | --- | --- | | મંદા | 恒生指数 | 25935.90c 175.17 | 0.68% | | | HSTECH 恒生科技 | | 5615.43c 80.51 1.45% | | | | HSBIO 恒生生物科技 | | 15575.91c 398.39 | 2.62% | | | HSCEI | 恒生中国企业指数 | 9106.48c 77.93 | 0.86% | | | HSCI | 恒生综合指数 | 3972.31 c 25.17 = | 0.64% | | 医药生物板块大涨，歌礼制药涨超11%，药明合联、药明生物涨超7%，药明康德等多股涨超5%。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | | --- | --- | --- | --- | | 1672 | 歌礼制药-B | 13.210c | 11.10% | | 2197 | 三叶草生物-B | 2.740 c | 10.04% | | 2268 | 药明合 ...

Market Overview - The Hong Kong stock market experienced a significant decline, with the Hang Seng Index falling by 1.28% to close at 25,760.73 points, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index dropped by 1.68% and 1.58%, respectively [1][2]. Sector Performance - Major technology stocks and large financial stocks collectively dragged down market sentiment, with notable declines in companies like Bilibili (-3%), NetEase (-2.94%), and Alibaba (-2.17%) [4][5]. - The financial sector also faced losses, particularly in insurance stocks, with China Pacific Insurance down by 4% and China Life Insurance down by over 3% [6]. - The biopharmaceutical sector saw declines, with WuXi AppTec falling by over 3% and other major players like BeiGene and WuXi Biologics also experiencing losses [7]. Commodity and Other Stocks - In contrast, stocks in the non-ferrous metals and precious metals sectors performed well, with China Molybdenum and China Aluminum rising by over 2% [8]. - Airline stocks strengthened, with China Eastern Airlines and China Southern Airlines both gaining over 2%, supported by a new action plan promoting the integration of cultural tourism and civil aviation [9]. Capital Flows - Southbound capital saw a net inflow of 2.279 billion HKD, indicating continued interest in Hong Kong stocks from mainland investors [9]. Future Outlook - Analysts suggest that the current market adjustments may create opportunities for recovery in 2026, with expectations of a necessary interest rate cut in December due to rising unemployment and declining real wages [11].

12月3日，港股今日低开低走，午后维持震荡下行态势，截止收盘，恒生指数跌1.28%报25760.73点，恒 生科技指数跌1.58%报5534.92点，国企指数跌1.68%报9028.55点，红筹指数跌0.9%报4239.39点。 盘面上，大型科技股集体走低，阿里巴巴跌2.17%，腾讯控股跌0.97%，京东集团跌0.43%，小米集团跌 1.18%，网易跌2.94%，美团跌0.62%，快手跌2.25%，哔哩哔哩跌3%；生物技术板块走弱，歌礼制药跌 超12%，药明合联跌超3%；新能源汽车股下跌，小鹏汽车跌超4%，蔚来跌超3%；应用软件板块跌幅居 前，微盟集团跌3.09%；内房股走弱，世茂集跌超3%；保险股下跌，中国人寿跌超3%；有色金属板块 上涨，中国铝业涨超4%，洛阳钼业涨近3%；今日两只新股上市，乐摩科技涨超36%，金岩高岭新材涨 超2%。 企业新闻 黑芝麻智能(02533.HK)：拟斥资约4亿-5.5亿元获取珠海亿智电子科技有限公司多数股权，预期收购事项 将于2026年第一季度完成。 中国秦发(00866.HK)：非全资附属SDE与浙江能源亚太订立供煤协议，将提供15万公吨的印度尼西亚燃 料煤。 复宏汉霖(0 ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

12月3日，港股指数低开低走，截止午盘，恒生指数跌0.97%报25842.77点，恒生科技指数跌1.3%报 5550.92点，国企指数跌1.26%报9067.4点，红筹指数跌0.64%报4250.67点。 盘面上，科技股集体弱势拖累大市走低，阿里巴巴跌1.97%，腾讯控股跌1.05%，京东集团跌0.26%，小 米集团跌0.79%，网易跌3.3%，美团跌0.67%，快手跌1.67%，哔哩哔哩跌2.7%；有色金属股活跃，中国 铝业涨超5%；汽车股走弱，小鹏汽车跌超3%；生物医药板块普跌，药明合联跌超3%；今日两只新股上 市，乐摩科技涨超56%，金岩高岭新材涨超1%。 企业新闻 中国东方集团(00581.HK)：斥资约5200万元收购江苏神通375.35万股股份。 黑芝麻智能(02533.HK)：拟斥资约4亿-5.5亿元获取珠海亿智电子科技有限公司多数股权，预期收购事项 将于2026年第一季度完成。 国富氢能(02582.HK)：完成配售485.8万股，净筹约1.97亿港元，约60%用于中国及海外氢能项目的融资 投资及合作。 中国秦发(00866.HK)：非全资附属SDE与浙江能源亚太订立供煤协议，将提供15万公吨 ...

每经AI快讯，港股生物医药板块延续走低，药明合联跌超3%，百济神州跌近2%，药明康德、君实生物 等跟跌。 ...

Core Viewpoint - The article discusses the increasing interaction between Chinese innovative drugs and global patients, highlighting the appeal of CAR-T therapy in China for international cancer patients due to lower costs and efficient treatment processes [1][3][4]. Group 1: CAR-T Therapy in China - CAR-T therapy is a personalized treatment that enhances the ability of T-cells to recognize and kill tumors, with significant development concentrated in China and the US [3]. - The cost of CAR-T drugs in China ranges from 1 million to 1.3 million yuan, approximately one-third of the price in the US, making it a more attractive option for patients [4][5]. - Over the past year, more than 100 overseas patients have consulted with medical institutions in China, with around 90% of completed CAR-T treatments being for international patients [6]. Group 2: Growth of China's Oncology Drug Ecosystem - China's oncology sector has attracted substantial R&D funding, with advancements spanning from early screening to late-stage treatment [7]. - The approval of new indications for existing drugs, such as the combination therapy for non-small cell lung cancer, showcases the rapid development in the oncology field [7]. - The increasing recognition of Chinese pharmaceutical innovation is evidenced by the number of breakthrough therapy designations granted by the FDA to Chinese products [11]. Group 3: International Expansion of Chinese Drugs - Chinese companies are increasingly recognized for their innovation, with significant international collaborations and licensing agreements, such as the partnership between Innovent Biologics and Takeda Pharmaceuticals [10]. - The global market for Chinese CAR-T products is expanding, with companies like Legend Biotech achieving substantial sales figures in the US [10]. - The trend of Chinese pharmaceutical companies seeking international markets is driven by the need for growth outside the competitive domestic landscape [13]. Group 4: Challenges and Opportunities - While the Chinese pharmaceutical industry is making strides, challenges remain in establishing a robust international presence and navigating regulatory environments [12]. - The potential for growth in medical tourism in China is significant, but improvements in visa policies and treatment timelines are necessary to enhance competitiveness [8]. - The future of China's innovative drug sector is uncertain, with investors closely monitoring government policies and market dynamics [13].

Core Viewpoint - The article highlights the significant impact of a fire incident in Hong Kong's Tai Po district, which resulted in major casualties and has drawn widespread attention from various sectors of society [1] Company Response - WuXi Biologics (02269) and its subsidiary WuXi AppTec announced a joint donation of HKD 10 million to support disaster relief efforts, focusing on medical treatment, emergency housing, material supplies, and post-disaster recovery for affected individuals [1] - The company expresses deep condolences for the victims and sincere sympathy for the affected individuals, while also honoring the rescue personnel working tirelessly [1] - WuXi Biologics and WuXi AppTec reaffirm their commitment to social responsibility, pledging to monitor the disaster situation and support the Hong Kong community in rebuilding efforts [1]